{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:55:03Z","timestamp":1790790903499,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Science and Technology Innovation Initiative","award":["21SQBS02302"],"award-info":[{"award-number":["21SQBS02302"]}]},{"name":"Cultivated Funding for Clinical Research Innovation, Renji Hospital, School of Medicine, Shanghai Jiaotong University","award":["RJPY-LX-004"],"award-info":[{"award-number":["RJPY-LX-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Predicting secondary loss of response (SLR) to infliximab (IFX) is paramount for tailoring personalized management regimens. Concurrent pancreatic manifestations in patients with Crohn\u2019s disease (CD) may correlate with SLR to anti-tumor necrosis factor treatment. This work aimed to evaluate the potential of pancreatic radiomics to predict SLR to IFX in biologic-naive individuals with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three models were developed by logistic regression analyses to identify high-risk subgroup prone to SLR. The area under the curve (AUC), calibration curve, decision curve analysis (DCA), and integrated discrimination improvement (IDI) were applied for the verification of model performance. A quantitative nomogram was proposed based on the optimal prediction model, and its reliability was substantiated by 10-fold cross-validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 184 CD patients were enrolled in the period January 2016 to February 2022. The clinical model incorporated age of onset, disease duration, disease location, and disease behavior, whereas the radiomics model consisted of five texture features. These clinical parameters and the radiomics score calculated by selected texture features were applied to build the combined model. Compared to other two models, combined model achieved favorable, significantly improved discrimination power (AUC\n                      <jats:sub>combined vs clinical<\/jats:sub>\n                      0.851 vs 0.694,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02; AUC\n                      <jats:sub>combined vs radiomics<\/jats:sub>\n                      0.851 vs 0.740,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and superior clinical usefulness, which was further converted into reliable nomogram with an accuracy of 0.860 and AUC of 0.872.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The first proposed pancreatic-related nomogram represents a credible, noninvasive predictive instrument to assist clinicians in accurately identifying SLR and non-SLR in CD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>This study first built a visual nomogram incorporating pancreatic texture features and clinical factors, which could facilitate clinicians to make personalized treatment decisions and optimize cost-effectiveness ratio for patients with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key points<\/jats:title>\n                    <jats:p>\u2022 The first proposed pancreatic-related model predicts secondary loss of response for infliximab in Crohn\u2019s disease.<\/jats:p>\n                    <jats:p>\u2022 The model achieved satisfactory predictive accuracy, calibration ability, and clinical value.<\/jats:p>\n                    <jats:p>\u2022 The model-based nomogram has the potential to identify long-term failure in advance and tailor personalized management regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-024-01637-4","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:10:01Z","timestamp":1710281401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically na\u00efve patients with Crohn\u2019s disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Tian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-1610","authenticated-orcid":false,"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","volume":"161","author":"G Rogler","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT (2021) Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology 161:1118\u20131132","journal-title":"Gastroenterology"},{"key":"1637_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park KT, Ehrlich OG, Allen JI et al (2020) The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation. Inflamm Bowel Dis 26:1\u201310","journal-title":"Inflamm Bowel Dis"},{"key":"1637_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/ajg.2015.207","volume":"111","author":"KT Park","year":"2016","unstructured":"Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A (2016) Health insurance paid costs and drivers of costs for patients with Crohn\u2019s disease in the United States. Am J Gastroenterol 111:15\u201323","journal-title":"Am J Gastroenterol"},{"key":"1637_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","volume":"10","author":"C Ha","year":"2012","unstructured":"Ha C, Ullman TA, Siegel CA, Kornbluth A (2012) Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 10:1002\u20131007. quiz e78","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1637_CR5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","volume":"154","author":"G D'Haens","year":"2018","unstructured":"D\u2019Haens G, Vermeire S, Lambrecht G et al (2018) Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease. Gastroenterology 154:1343\u201351.e1","journal-title":"Gastroenterology"},{"key":"1637_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MOG.0000000000000536","volume":"35","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS (2019) Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol 35:302\u2013310","journal-title":"Curr Opin Gastroenterol"},{"key":"1637_CR7","doi-asserted-by":"publisher","first-page":"e0186575","DOI":"10.1371\/journal.pone.0186575","volume":"12","author":"F Scaldaferri","year":"2017","unstructured":"Scaldaferri F, D\u2019Ambrosio D, Holleran G et al (2017) Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS One 12:e0186575","journal-title":"PLoS One"},{"key":"1637_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","volume":"6","author":"MB Sprakes","year":"2012","unstructured":"Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J (2012) Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn\u2019s disease: a large single centre experience. J Crohns Colitis 6:143\u2013153","journal-title":"J Crohns Colitis"},{"key":"1637_CR9","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/00365521.2019.1638962","volume":"54","author":"JH Song","year":"2019","unstructured":"Song JH, Hong SN, Lee JE et al (2019) C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor \u03b1 induction therapy predicts secondary loss of response in patients with Crohn\u2019s disease. Scand J Gastroenterol 54:876\u2013885","journal-title":"Scand J Gastroenterol"},{"key":"1637_CR10","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/ibd.21219","volume":"16","author":"U Navaneethan","year":"2010","unstructured":"Navaneethan U, Shen B (2010) Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 16:1598\u20131619","journal-title":"Inflamm Bowel Dis"},{"key":"1637_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/MCG.0b013e3181cadbe1","volume":"44","author":"CS Pitchumoni","year":"2010","unstructured":"Pitchumoni CS, Rubin A, Das K (2010) Pancreatitis in inflammatory bowel diseases. J Clin Gastroenterol 44:246\u2013253","journal-title":"J Clin Gastroenterol"},{"key":"1637_CR12","first-page":"136","volume":"16","author":"S Jasdanwala","year":"2015","unstructured":"Jasdanwala S, Babyatsky M (2015) Crohn\u2019s disease and acute pancreatitis. JOP 16:136\u2013142","journal-title":"JOP"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/medicina57050473","volume":"57","author":"P Jakimiec","year":"2021","unstructured":"Jakimiec P, Zdanowicz K, Kwiatek-Sredzinska K, Filimoniuk A, Lebensztejn D, Daniluk U (2021) Pancreatic disorders in children with inflammatory bowel disease. Medicina (Kaunas) 57:473","journal-title":"Medicina (Kaunas)"},{"key":"1637_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00004836-199312000-00004","volume":"17","author":"P Weber","year":"1993","unstructured":"Weber P, Seibold F, Jenss H (1993) Acute pancreatitis in Crohn\u2019s disease. J Clin Gastroenterol 17:286\u2013291","journal-title":"J Clin Gastroenterol"},{"key":"1637_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/MPA.0000000000000261","volume":"44","author":"T Ueki","year":"2015","unstructured":"Ueki T, Kawamoto K, Otsuka Y et al (2015) Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease. Pancreas 44:434\u2013440","journal-title":"Pancreas"},{"key":"1637_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/jcm8070916","volume":"8","author":"T Iida","year":"2019","unstructured":"Iida T, Wagatsuma K, Hirayama D, Yokoyama Y, Nakase H (2019) The etiology of pancreatic manifestations in patients with inflammatory bowel disease. J Clin Med 8:916","journal-title":"J Clin Med"},{"key":"1637_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1572-0241.1999.01015.x","volume":"94","author":"B Heikius","year":"1999","unstructured":"Heikius B, Niemel\u00e4 S, Lehtola J, Karttunen TJ (1999) Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol 94:1062\u20131069","journal-title":"Am J Gastroenterol"},{"key":"1637_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-2002-19636","volume":"40","author":"B Bokemeyer","year":"2002","unstructured":"Bokemeyer B (2002) Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn\u2019s disease and ulcerative colitis. Z Gastroenterol 40:5\u201310","journal-title":"Z Gastroenterol"},{"key":"1637_CR19","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/ard.2005.037903","volume":"64","author":"E Krishnan","year":"2005","unstructured":"Krishnan E, H\u00e4kkinen A, Sokka T, Hannonen P (2005) Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 64:1350\u20131352","journal-title":"Ann Rheum Dis"},{"key":"1637_CR20","doi-asserted-by":"publisher","first-page":"e9930","DOI":"10.1097\/MD.0000000000009930","volume":"97","author":"B Armagan","year":"2018","unstructured":"Armagan B, Sari A, Erden A et al (2018) Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results. Medicine (Baltimore) 97:e9930","journal-title":"Medicine (Baltimore)"},{"key":"1637_CR21","doi-asserted-by":"publisher","first-page":"e000351","DOI":"10.1136\/bmjgast-2019-000351","volume":"7","author":"I Marin-Jimenez","year":"2020","unstructured":"Marin-Jimenez I, Bastida G, For\u00e9s A et al (2020) Impact of comorbidities on anti-TNF\u03b1 response and relapse in patients with inflammatory bowel disease: the VERNE study. BMJ Open Gastroenterol 7:e000351","journal-title":"BMJ Open Gastroenterol"},{"key":"1637_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00259-016-3506-2","volume":"44","author":"M Nakajo","year":"2017","unstructured":"Nakajo M, Jinguji M, Nakabeppu Y et al (2017) Texture analysis of (18)F-FDG PET\/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging 44:206\u2013214","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1637_CR23","doi-asserted-by":"publisher","first-page":"e0227492","DOI":"10.1371\/journal.pone.0227492","volume":"15","author":"S Jang","year":"2020","unstructured":"Jang S, Kim JH, Choi SY, Park SJ, Han JK (2020) Application of computerized 3D-CT texture analysis of pancreas for the assessment of patients with diabetes. PLoS One 15:e0227492","journal-title":"PLoS One"},{"key":"1637_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s11605-015-2855-7","volume":"19","author":"S Yardimci","year":"2015","unstructured":"Yardimci S, Kara YB, Tuney D et al (2015) A simple method to evaluate whether pancreas texture can be used to predict pancreatic fistula risk after pancreatoduodenectomy. J Gastrointest Surg 19:1625\u20131631","journal-title":"J Gastrointest Surg"},{"key":"1637_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13:144\u2013164","journal-title":"J Crohns Colitis"},{"key":"1637_CR26","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.2147\/JIR.S314912","volume":"14","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li H, Feng J, Suo S, Feng Q, Shen J (2021) A novel radiomics nomogram for the prediction of secondary loss of response to infliximab in Crohn\u2019s disease. J Inflamm Res 14:2731\u20132740","journal-title":"J Inflamm Res"},{"key":"1637_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis 11:3\u201325","journal-title":"J Crohns Colitis"},{"key":"1637_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ (2018) Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis 12:635\u2013643","journal-title":"J Crohns Colitis"},{"key":"1637_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/apt.12237","volume":"37","author":"NS Patel","year":"2013","unstructured":"Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R (2013) Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 37:630\u2013639","journal-title":"Aliment Pharmacol Ther"},{"key":"1637_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.diii.2021.12.003","volume":"103","author":"JP Tasu","year":"2022","unstructured":"Tasu JP, Guen RL, Rhouma IB et al (2022) Accuracy of a CT density threshold enhancement to identify pancreatic parenchyma necrosis in acute pancreatitis during the first week. Diagn Interv Imaging 103:266\u2013272","journal-title":"Diagn Interv Imaging"},{"key":"1637_CR31","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3348\/kjr.2020.1343","volume":"22","author":"J Kim","year":"2021","unstructured":"Kim J, Albakheet SS, Han K et al (2021) Quantitative MRI assessment of pancreatic steatosis using proton density fat fraction in pediatric obesity. Korean J Radiol 22:1886\u20131893","journal-title":"Korean J Radiol"},{"key":"1637_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1148\/radiol.13122883","volume":"271","author":"SY Kim","year":"2014","unstructured":"Kim SY, Kim H, Cho JY et al (2014) Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology 271:104\u2013112","journal-title":"Radiology"},{"key":"1637_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00330-018-5611-z","volume":"29","author":"SCN Hui","year":"2019","unstructured":"Hui SCN, Wong SKH, Ai Q, Yeung DKW, Ng EKW, Chu WCW (2019) Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI. Eur Radiol 29:849\u2013856","journal-title":"Eur Radiol"},{"key":"1637_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1148\/radiol.2502080849","volume":"250","author":"AC Braithwaite","year":"2009","unstructured":"Braithwaite AC, Dale BM, Boll DT, Merkle EM (2009) Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 250:459\u2013465","journal-title":"Radiology"},{"key":"1637_CR35","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 78:4786\u20134789","journal-title":"Cancer Res"},{"key":"1637_CR36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295:328\u2013338","journal-title":"Radiology"},{"key":"1637_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00259-020-04924-6","volume":"48","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhao X, Zhang J, Han J, Dai M (2021) Value of (18)F-FDG PET\/CT radiomic features to distinguish solitary lung adenocarcinoma from tuberculosis. Eur J Nucl Med Mol Imaging 48:231\u2013240","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1637_CR38","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jcmg.2013.09.006","volume":"6","author":"SJ Kang","year":"2013","unstructured":"Kang SJ, Cho YR, Park GM et al (2013) Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging. JACC Cardiovasc Imaging 6:1183\u20131190","journal-title":"JACC Cardiovasc Imaging"},{"key":"1637_CR39","doi-asserted-by":"publisher","first-page":"e201304002","DOI":"10.5936\/csbj.201304002","volume":"7","author":"B Wang","year":"2013","unstructured":"Wang B (2013) A two-stage peak alignment algorithm for two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Comput Struct Biotechnol J 7:e201304002","journal-title":"Comput Struct Biotechnol J"},{"key":"1637_CR40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology 132:863\u2013873. quiz 1165-6","journal-title":"Gastroenterology"},{"key":"1637_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","volume":"2","author":"M Ferrante","year":"2008","unstructured":"Ferrante M, Vermeire S, Fidder H et al (2008) Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2:219\u2013225","journal-title":"J Crohns Colitis"},{"key":"1637_CR42","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","volume":"97","author":"S Vermeire","year":"2002","unstructured":"Vermeire S, Louis E, Carbonez A et al (2002) Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn\u2019s disease. Am J Gastroenterol 97:2357\u20132363","journal-title":"Am J Gastroenterol"},{"key":"1637_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ecco-jcc\/jjv059","volume":"9","author":"S Taleban","year":"2015","unstructured":"Taleban S, Colombel JF, Mohler MJ, Fain MJ (2015) Inflammatory bowel disease and the elderly: a review. J Crohns Colitis 9:507\u2013515","journal-title":"J Crohns Colitis"},{"key":"1637_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/1751-2980.12698","volume":"20","author":"QW Zhang","year":"2019","unstructured":"Zhang QW, Shen J, Zheng Q, Ran ZH (2019) Loss of response to scheduled infliximab therapy for Crohn\u2019s disease in adults: a systematic review and meta-analysis. J Dig Dis 20:65\u201372","journal-title":"J Dig Dis"},{"key":"1637_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/ecco-jcc\/jjw038","volume":"10","author":"C Dupont-Lucas","year":"2016","unstructured":"Dupont-Lucas C, Sternszus R, Ezri J et al (2016) Identifying patients at high risk of loss of response to infliximab maintenance therapy in paediatric Crohn\u2019s disease. J Crohns Colitis 10:795\u2013804","journal-title":"J Crohns Colitis"},{"key":"1637_CR46","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1365-2036.2012.05100.x","volume":"35","author":"F Zorzi","year":"2012","unstructured":"Zorzi F, Zuzzi S, Onali S et al (2012) Efficacy and safety of infliximab and adalimumab in Crohn\u2019s disease: a single centre study. Aliment Pharmacol Ther 35:1397\u20131407","journal-title":"Aliment Pharmacol Ther"},{"key":"1637_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cgh.2013.08.026","volume":"12","author":"GW Moran","year":"2014","unstructured":"Moran GW, Dubeau MF, Kaplan GG et al (2014) Phenotypic features of Crohn\u2019s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol 12:434\u201342.e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1637_CR48","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","volume":"14","author":"JP Gisbert","year":"2020","unstructured":"Gisbert JP, Chaparro M (2020) Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 14:694\u2013709","journal-title":"J Crohns Colitis"},{"key":"1637_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 132:52\u201365","journal-title":"Gastroenterology"},{"key":"1637_CR50","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/ajg.2010.78","volume":"105","author":"S Schreiber","year":"2010","unstructured":"Schreiber S, Colombel JF, Bloomfield R et al (2010) Increased response and remission rates in short-duration Crohn\u2019s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 105:1574\u20131582","journal-title":"Am J Gastroenterol"},{"key":"1637_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14:329\u2013342","journal-title":"Nat Rev Immunol"},{"key":"1637_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fonc.2020.00198","volume":"10","author":"J Gao","year":"2020","unstructured":"Gao J, Huang X, Meng H et al (2020) Performance of multiparametric functional imaging and texture analysis in predicting synchronous metastatic disease in pancreatic ductal adenocarcinoma patients by hybrid PET\/MR: initial experience. Front Oncol 10:198","journal-title":"Front Oncol"},{"key":"1637_CR53","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/dote.12170","volume":"28","author":"C Yip","year":"2015","unstructured":"Yip C, Davnall F, Kozarski R et al (2015) Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. Dis Esophagus 28:172\u2013179","journal-title":"Dis Esophagus"},{"key":"1637_CR54","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","volume":"38","author":"RD Riley","year":"2019","unstructured":"Riley RD, Snell KI, Ensor J et al (2019) Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med 38:1276\u20131296","journal-title":"Stat Med"},{"key":"1637_CR55","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12874-023-02008-1","volume":"23","author":"P Dhiman","year":"2023","unstructured":"Dhiman P, Ma J, Qi C et al (2023) Sample size requirements are not being considered in studies developing prediction models for binary outcomes: a systematic review. BMC Med Res Methodol 23:188","journal-title":"BMC Med Res Methodol"},{"key":"1637_CR56","doi-asserted-by":"publisher","first-page":"e2200302","DOI":"10.1002\/bimj.202200302","volume":"65","author":"RD Riley","year":"2023","unstructured":"Riley RD, Collins GS (2023) Stability of clinical prediction models developed using statistical or machine learning methods. Biom J 65:e2200302","journal-title":"Biom J"},{"key":"1637_CR57","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1053\/j.gastro.2019.07.032","volume":"157","author":"L Gonczi","year":"2019","unstructured":"Gonczi L, Bessissow T, Lakatos PL (2019) Ver(s)ifying the efficacy of vedolizumab therapy on mucosal healing in patients with Crohn\u2019s disease. Gastroenterology 157:925\u2013927","journal-title":"Gastroenterology"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-024-01637-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01637-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:10:23Z","timestamp":1710281423000},"score":1,"resource":{"primary":{"URL":"https:\/\/insightsimaging.springeropen.com\/articles\/10.1186\/s13244-024-01637-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1186\/s13244-024-01637-4","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was permitted by the Ethics Committee of our institution and the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}